Wilmington, DE | October 02, 2023 –  NuggMD, the nation’s leading medical marijuana telemedicine platform, is launching its service in Delaware for just $99 for a limited time. Since its founding in 2015, NuggMD has connected over 1,000,000 patients to their medical marijuana physicians.

It’s legal to possess and use cannabis in the state, but adult-use sales aren’t expected to begin until November 2024 at the soonest, and more likely later in 2025.

Medical patients in the state opposed the option to allow the existing, tightly-regulated medical dispensaries to begin adult-use sales earlier due to fears that there wouldn’t be enough cannabis to serve both medical and recreational needs, which would cause a spike in prices.

“It’s understandable that patients would be worried about a spike in prices with an uncontrolled launch of recreational sales,” says Alex Milligan, CMO and co-founder of NuggMD. “It has happened in other states, leaving patients in a bad situation. But the current situation brings about other safety concerns. State residents can possess cannabis and use it legally, but can’t buy safe, tested weed unless they’re patients.”

“I don’t suggest you turn to the black market while waiting for dispensaries to open,” says Kam Babazade, COO and co-founder of NuggMD. “Recent tests on black market products on the East Coast have shown contaminants, synthetic cannabinoids, and major discrepancies in potency. This is something you especially want to avoid if you have significant medical issues.”

“We have diverted over a million patients from the black market now,” says Collin Mann, NuggMD co-founder and CEO. “Delaware was wise to allow telemedicine so even more patients can be turned toward the legal, tested, and safe products in the state’s existing dispensaries.”

NuggMD’s platform is available from 8 am to 10 pm seven days a week. No appointment is needed, and patients who don’t qualify for their state’s medical cannabis program won’t be charged for their evaluation.

About NuggMD

NuggMD is the nation’s leading medical marijuana technology platform, serving patients in California, Connecticut, Delaware, Georgia, Illinois, Iowa, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Delaware, Nevada, New Jersey, New York, Ohio, Oklahoma, Pennsylvania, Texas, Vermont, Virginia, Washington, and West Virginia. They’ve connected over 1,000,000 patients face-to-face with their new medical marijuana doctors via their state-of-the-art telemedicine platform. They believe every human being has the right to explore the benefits of medical cannabis and are fully committed to helping each patient explore every option in their journey to wellness. For further information, visit NuggMD.com/Delaware.

Contact Details

Andrew Graham

+1 646-385-0189

andrew.g@getnugg.com

Company Website

http://www.nuggmd.com

US$22 million transaction, including minimal US$1.5 million cash component, expected to be immediately accretive on an EBITDA and cashflow basis

8,500 square foot dispensary located in close proximity to Delaware, with no other dispensaries within a 25-mile radius

TORONTO, June 08, 2023 (GLOBE NEWSWIRE) — TerrAscend Corp. (“TerrAscend” or the “Company”) (CSE: TER) (OTCQX: TRSSF), a leading North American cannabis operator, today announced that on June 7, 2023 it entered into a definitive agreement to acquire Derby 1, LLC (d/b/a “Peninsula Alternative Health”), a medical dispensary in Maryland. The transaction will add a second dispensary to the Company’s Maryland footprint in advance of adult-use sales, which will begin on July 1, 2023. Under the terms of the agreement, TerrAscend will acquire Peninsula Alternative Health (“Peninsula”) for total consideration of US$22.1 million (the “Transaction”), including US$1.5 million in cash, with the remainder in a combination of existing debt, a seller’s note, and stock. The transaction, which is expected to be immediately accretive to TerrAscend on an EBITDA and cashflow basis, is subject to customary closing conditions, including regulatory approval.

Peninsula Alternative Health is one of the highest performing medical dispensaries in Maryland with a net revenue run rate in 2023 of approximately US$14 million. Strategically located near the Delaware border in Salisbury, Maryland, this 8,500 square foot dispensary has no direct competitor within a 25-mile radius. TerrAscend expects to achieve significant sales and margin improvement by supplying a complete selection of its high-quality brands including Kind Tree, Gage, Cookies and Wana. Following the close of the Transaction, TerrAscend’s retail footprint will increase to 35 dispensaries nationwide.

“Adding a second, high-performing medical dispensary in Maryland is an important step in our strategy to become a market leader in the state,” said Jason Wild, Executive Chairman of TerrAscend. “We expect Peninsula to quickly become one of our highest performing dispensaries nationwide. With less than 30 days until the launch of adult use in Maryland, we are focused on additional acquisitions and reaching the four-dispensary cap as our northeast business unit will soon be operating in Maryland under the same successful business model we built in NJ.”

The Canadian Securities Exchange (“CSE”) has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

About TerrAscend
TerrAscend is a leading North American cannabis operator with vertically integrated operations in Pennsylvania, New Jersey, Maryland, Michigan and California and retail operations in Canada. TerrAscend operates The Apothecarium and Gage dispensary retail locations as well as scaled cultivation, processing, and manufacturing facilities in its core markets. TerrAscend’s cultivation and manufacturing practices yield consistent, high-quality cannabis, providing industry-leading product selection to both the medical and legal adult-use markets. The Company owns several synergistic businesses and brands including Gage Cannabis, The Apothecarium, Ilera Healthcare, Kind Tree, Legend, State Flower, and Valhalla Confections. For more information visit www.terrascend.com.

Caution Regarding Cannabis Operations in the United States
Investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States. Cannabis remains a Schedule I drug under the US Controlled Substances Act, making it illegal under federal law in the United States to, among other things, cultivate, distribute, or possess cannabis in the United States. Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable US federal money laundering legislation.

While the approach to enforcement of such laws by the federal government in the United States has trended toward non-enforcement against individuals and businesses that comply with medical or adult-use cannabis programs in states where such programs are legal, strict compliance with state laws with respect to cannabis will neither absolve TerrAscend of liability under U.S. federal law, nor will it provide a defense to any federal proceeding which may be brought against TerrAscend. The enforcement of federal laws in the United States is a significant risk to the business of TerrAscend and any proceedings brought against TerrAscend thereunder may adversely affect TerrAscend’s operations and financial performance.

Forward Looking Information
This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, and include statements with respect to future revenue and profits. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment, and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to, the success of the launch of adult use sales in Maryland and in the Peninsula transaction specifically, current and future market conditions; risks related to federal, state, provincial, territorial, local and foreign government laws, rules and regulations, including federal and state laws in the United States relating to cannabis operations in the United States; and the risk factors set out in the Company’s most recently filed MD&A, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR at www.sedar.com and in the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission on March 16, 2023.

The statements in this press release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether, as a result of new information, future events, or results or otherwise, other than as required by applicable securities laws.

For more information regarding TerrAscend:
Keith Stauffer
Chief Financial Officer
717-343-5386
IR@terrascend.com

Briana Chester
MATTIO Communications
424-465-4419
terrascend@mattio.com

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

NORWOOD, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) — MariMed, Inc. (OTCQX: MRMD) (“MariMed” or the “Company”), a leading multi-state cannabis operator focused on improving lives every day, today announced that its award-winning cannabis brands and products are now available in Delaware. As a result of new regulations in the Delaware Medical Marijuana program, MariMed has expanded its licensing agreement with First State Compassion Center (“FSC”), a leading Delaware vertically integrated cannabis operator, to produce and distribute its branded cannabis edibles.

First State Compassion will have exclusive rights to produce and distribute MariMed’s Betty’s Eddies® infused fruit chews, Bubby’s Baked soft and chewy, full-spectrum cannabis baked bites, and k FUSION chewable micro-dose mints. MariMed and FSC have a longstanding advisory relationship. FSC currently licenses MariMed’s Nature’s Heritage® premium flower and concentrates brand.

“FSC is delighted to provide these fantastic products designed to meet the needs of the patients in the Delaware Medical Cannabis program,” said Mark Lally, CEO of First State Compassion. “We are proud that MariMed has trusted our team to produce its valued brands to the required quality levels.”

“We are thrilled to bring our popular portfolio of edibles brands to Delaware,” said Bob Fireman, Chief Executive Officer of MariMed. “We have enjoyed a tremendous working relationship with First State Compassion and know that it will produce our products with the same consistency, great taste, and great experience that our brands deliver in many other markets.”

With the addition of Delaware, MariMed’s brands will now be available in six states plus Puerto Rico with more to come in the future.

For more information on MariMed and its brands, please visit www.marimedinc.com.

About MariMed

MariMed Inc., a multi-state cannabis operator, is dedicated to improving lives every day through its high-quality products, its actions, and its values. The Company develops, owns, and manages seed to sale state-licensed cannabis facilities, which are models of excellence in horticultural principles, cannabis cultivation, cannabis-infused products, and dispensary operations. MariMed has an experienced management team that has produced consistent growth and success for the Company and its managed business units. Proprietary formulations created by the Company’s technicians are embedded in its top-selling and award-winning products and brands, including Betty’s Eddies®, Nature’s Heritage®, Bubby’s Baked, k FUSION, and Kalm FUSION®. For additional information, visit www.marimedinc.com.

Investor Relations Contact:
Steve West
Vice President, Investor Relations
Email: [email protected]

Media Contact:
Trailblaze PR
Email: [email protected]

Company Contact:
Howard Schacter
Chief Communications Officer
Email: [email protected]

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

<!– (adsbygoogle = window.adsbygoogle || []).push({ google_ad_client: “ca-pub-5707738102681835”, enable_page_level_ads: true }); –>

<!– Click –>